Lipo-CvsTesamorelin + Ipamorelin

Lipo-C is a multi-component lipotropic formulation where each ingredient targets a different aspect of fat metabolism. The MIC complex (methionine, inositol, choline) forms the core. Methionine is an essential amino acid that serves as a methyl donor and precursor to S-adenosyl methionine (SAM), which is required for the methylation of phospholipids in the liver — a process critical for packaging and exporting triglycerides as VLDL particles. Without adequate methionine, fat accumulates in hepatocytes.

Inositol, specifically myo-inositol, functions as a second messenger in insulin signaling pathways and is involved in phospholipid synthesis. It enhances insulin sensitivity at the cellular level and plays a role in serotonin receptor function, which may help regulate appetite and mood during caloric restriction. Choline is the precursor to phosphatidylcholine, the primary phospholipid component of cell membranes and lipoprotein particles. Choline deficiency directly causes hepatic steatosis (fatty liver) because the liver cannot package and export triglycerides without sufficient phosphatidylcholine.

The formulation is typically augmented with vitamin B12 (cyanocobalamin or methylcobalamin), which is a cofactor for methionine synthase and required for proper methylation cycle function, and L-carnitine, which transports long-chain fatty acids across the inner mitochondrial membrane for beta-oxidation. Together, the components support hepatic fat processing, mitochondrial fat burning, and the metabolic methylation pathways that connect them. The clinical evidence for MIC injections specifically is limited, though the biochemical rationale for each individual component in fat metabolism is well-established.

The Tesamorelin + Ipamorelin combination pairs the only FDA-approved GHRH analogue with the most selective growth hormone secretagogue, creating a dual-pathway approach similar in principle to CJC-1295/Ipamorelin but with tesamorelin's unique advantages for body composition.

Tesamorelin activates the GHRH receptor on pituitary somatotrophs through the Gs/cAMP/PKA pathway, stimulating GH gene transcription and secretion. Its trans-3-hexenoic acid modification at position 1 provides enhanced receptor affinity and modest DPP-IV resistance compared to native GHRH. Ipamorelin simultaneously activates the GHS-R1a receptor via the Gq/11/PLC/calcium pathway, providing the same synergistic amplification of GH pulses described for the CJC/Ipa combination.

The distinguishing advantage of tesamorelin in this stack is its clinically demonstrated effect on visceral adipose tissue (VAT). In multiple randomized controlled trials for HIV-associated lipodystrophy, tesamorelin reduced trunk fat by 15-18% over 6 months, with visceral fat reduction being proportionally greater than subcutaneous fat reduction. This preferential visceral fat mobilization occurs because visceral adipocytes express the highest density of GH receptors and are most responsive to GH-mediated hormone-sensitive lipase activation. The GH elevations produced by tesamorelin/ipamorelin combination may be greater than tesamorelin alone (due to the synergistic dual-pathway effect), potentially enhancing this visceral fat-targeting effect. The combination also benefits from tesamorelin's full-length GHRH sequence (44 amino acids vs 29 for CJC-1295), which may provide more complete receptor activation, and from the preserved pulsatility that both agents maintain through intact somatostatin feedback regulation.